NoMoCan Pharmaceuticals
First in Class targeted therapies for aggressive cancers with unmet medical needs, featuring selective diagnostic and prognostic tests.
| Date | Investors | Amount | Round |
|---|---|---|---|
$740k | Seed | ||
| Total Funding | 000k | ||
NomoCan Pharmaceuticals is a pioneering biotech company based in New York, specializing in the development of targeted therapies for some of the most aggressive cancers with unmet medical needs. The company's flagship product, NMC 001, is a monoclonal antibody that targets a specific pancreatic cancer marker, enabling selective identification and diagnosis of pancreatic cancer in humans. NMC 001 has demonstrated potent anti-tumor efficacy in rodent models, showing high affinity for its target.
NomoCan's platform technology not only provides a selective and specific diagnostic and prognostic test for early detection of cancer but also offers innovative treatment options. The company serves patients affected by devastating diseases, focusing on improving survival rates and quality of life.
Operating in the biopharmaceutical market, NomoCan's business model revolves around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies.
Keywords: targeted therapies, monoclonal antibody, pancreatic cancer, diagnostic tests, prognostic tests, anti-tumor efficacy, biopharmaceutical, unmet medical needs, clinical trials, platform technology.